Dare Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Dare Bioscience, Inc. (NASDAQ:DARE) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 314,953 shares, a decline of 32.4% from the December 15th total of 466,123 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average trading volume of 202,947 shares, the days-to-cover ratio is presently 1.6 days. Based on an average trading volume of 202,947 shares, the days-to-cover ratio is presently 1.6 days. Approximately 2.3% of the company’s shares are sold short.

Dare Bioscience Stock Up 1.3%

DARE traded up $0.03 during trading on Friday, reaching $1.98. 21,806 shares of the stock traded hands, compared to its average volume of 60,740. The stock’s 50-day simple moving average is $1.95 and its two-hundred day simple moving average is $2.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.18 and a quick ratio of 1.18. Dare Bioscience has a fifty-two week low of $1.61 and a fifty-two week high of $9.19. The stock has a market cap of $28.22 million, a price-to-earnings ratio of -1.06 and a beta of 0.78.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. The firm had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.01 million. As a group, equities research analysts expect that Dare Bioscience will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. boosted its holdings in Dare Bioscience by 810.6% in the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 13,650 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Dare Bioscience during the 3rd quarter worth about $37,000. Finally, AMH Equity Ltd boosted its stake in shares of Dare Bioscience by 20.0% during the 3rd quarter. AMH Equity Ltd now owns 232,373 shares of the biotechnology company’s stock worth $488,000 after acquiring an additional 38,770 shares in the last quarter. Institutional investors own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Dare Bioscience in a research report on Tuesday, December 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.00.

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.